Publications

Conference Presentations

Pracinostat

Dec 2016

Garcia-Manero et al. A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. ASH Annual Meeting, December 2016

Presentation
Dec 2015

Garcia-Manero et al. Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). ASH Annual Meeting, December 2015

Presentation
Dec 2015

Garcia-Manero et al. A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS). ASH Annual Meeting, December 2015

Presentation
Jun 2015

Garcia-Manero et al.Updated Results from a Phase 2 Study of Pracinostat in Combination With Azacitidine in Elderly Patients With Acute Myeloid Leukemia. EHA Annual Congress, June 2015

Poster
Dec 2014

Garcia-Manero et al. Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients With Previously Untreated Acute Myeloid Leukemia. ASH Annual Meeting, Dec 2014

Poster
Apr 2014

Sooraj et al. Activated Transcription Factor 3 (ATF-3) Expression is a Potential Marker of Tumor Response to the HDAC Inhibitor Pracinostat.AACR Annual Meeting, Apr 2014

Poster
Dec 2012

Quintas Cardama et al. Very high rates of clinical and cytogenetic response with the combination of the histone deacetylase inhibitor Pracinostat (SB939) and 5-Azacitidine in high-risk myelodysplastic syndrome.ASH Annual Meeting, Dec 2012

Poster
Dec 2011

Quintas Cardama et al. Therapy with the histone deacetylase inhibitor Pracinostat (SB939) in patients with myelofibrosis.ASH Annual Meeting, Dec 2011

Poster
Dec 2010

Garcia-Manero et al. Phase 1 study of the oral deacetylase inhibitor, SB939, in patients with advanced hematologic malignancies. ASH Annual Meeting, Dec 2010

Poster
Apr 2010

Novotny-Diermayr et al. The histone deacetylase inhibitor SB939 acts synergistically with Sorafenib in an orthotopic model of hepatocellular carcinoma. AACR Annual Meeting, Apr 2010

Poster
May 2009

Yong et al. Phase I study of SB939 three times weekly for 3 weeks every 4 weeks in patients with advanced solid malignancies. ASCO Annual Meeting, May 2009

Abstract
Oct 2008

Yong et al. A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies. EORTC-NCI-AACR International Conference: Molecular Targets and Cancer Therapeutics, Oct 2008

Poster
Dec 2007

Sangthongpitag et al. SB939: a potent and orally active HDAC inhibitor for the treatment of hematolgical malignancies.ASH Annual Meeting, Dec 2007

Abstract
Nov 2007

Sangthongpitag et al. SB939: a potent, orally active HDAC inhibitor for the treatment of haematolgic malignancies and solid tumors. AACR Centennial Conference on Translational Cancer Medicine, Nov 2007

Abstract
Oct 2007

Sangthongpitag et al. SB939: a potent and orally active HDAC inhibitor for the treatment of colorectal cancer. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Oct 2007

Abstract

ME-401

Nov 2016

Zann et al. Formulation selection and development for ME-401, an oral, potent and selective inhibitor of phosphoinositide 3-kinase P110δ during a first-in-human study in healthy volunteers. AAPS Annual Meeting, Nov 2016

Poster
Apr 2016

Moreno et al. Clinical Pharmacokinetics and Pharmacodynamics of ME-401, an Oral, Potent and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers. AACR Annual Meeting, Apr 2016

Poster
Dec 2012

O'Farrell et al. Preclinical characterization of PWT143, a novel selective and potent phosphatidylinositol 3-kinase delta (PI3K delta) inhibitor with ex-vivoactivity in hematologic malignancies. ASH Annual Meeting, Dec 2012

Poster
Jun 2012

Matthews et al. Discovery of PI3K delta inhibitors for the treatment of inflammatory and autoimmune disease. The New York Academy of Sciences: Inositol Phospholipid Signaling in Physiology and Disease, June 2012

Poster

ME-344

Apr 2015

Manevich et al. ME-344, a Novel Isoflavone with Activity as a Mitochondrial Oxygenase Inhibitor. AACR Annual Meeting, Apr 2015

Poster
Oct 2013

Bendell et al. ME-344, a Novel Mitochondrial Oxygenase Inhibitor: Results From a First-In-Human Phase I Study.AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 2013

Poster
Apr 2013

Alvero et al. ME-344 delays tumor kinetics in an ovarian cancer in vivo recurrence model. AACR Annual Meeting, Apr 2013

Poster
Apr 2011

Alvero et al. Depression of mitochondrial bioenergetics is a potent death stimulus in the ovarian cancer stem cells.AACR Annual Meeting, Apr 2011

Poster
Nov 2010

Alvero et al. Targeting the mitochondria activates two independent pathways leading to caspase-independent cell death in ovarian cancer stem cells.World Congress on Targeting Mitochondria, Nov 2010

Press Release
Apr 2009

Mor et al. NV-128, a novel isoflavone derivative, targets the mTOR pathway and induces cell death in epithelial ovarian cancer stem cells. AACR Annual Meeting, Apr 2009

Abstract
Oct 2007

Mor et al. Activation of caspase-independent programmed cell death overcomes apoptosis resistance in ovarian cancer cells. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Oct 2007

Abstract
Apr 2007

Alvero et al. Autophage precedes caspase-independent cell death in chemo-resistant ovarian cancer cells. AACR Annual Meeting, Apr 2007

Abstract
Jun 2012

Kurkjian C, Pant S, Burris HA, Bendell JC, Jones SF, Moore KN, Moreno O, Mass RD, Infante JR. ME-143, a novel inhibitor of tumor-specific NADH oxidase (tNOX): Results from a first-in-human phase I study . ASCO Annual Meeting , Jun 2012 .

Poster
Jun 2010

Gibney G, Elfiky A, Bussom S, Hoimes CJ, Burns A, McDonough JA, Rowen E, Cheng YC, Kelly WK. A phase II study of oral phenoxodiol in castrate and noncastrate prostate cancer patients with associated cytokine changes. ASCO Annual Meeting , Jun 2010 .

Abstract
Apr 2009

Saif M, Brown D, Husband A. Pre-clinical toxicology of triphendiol. AACR Annual Meeting , Apr 2009 .

Abstract
Feb 2009

Elfiky A, Clark J, Rowen E, Chao H, Delvy M, Israel G, Kelly W. Phase II study of oral phenoxodiol in patients with castrate and non-castrate prostate cancer. ASCO Genitourinary Cancers Symposium , Feb 2009 .

Abstract
Apr 2008

Wang X, Kim K, Alvero A, Mor G, Thompson J, Brown D, Tytler E. Triphendiol (NV-196) induces apoptosis and sensitizes pancreatic cancer cells to gemcitabine. AACR Annual Meeting , Apr 2008 .

Abstract
Jul 2007

McKernan R, Tytler E, McDougall F, Whiting A, Husband A, Brown D. Development of NV-196 as a gemcitabine chemo-sensitizer for treatment of pancreatic adenocarcinoma and cholangiocarcinoma.Discovery Science and Biotechnology Meeting , Jul-Aug 2007 .

Apr 2007

Mahoney S, Brown D, Kelly G, Millward M, Dharmarajan A. The effects of phenoxodiol on the ß-catenin pathway in prostate cancer. AACR Annual Meeting , Apr 2007 .

Abstract
Sep 2006

Morre DJ, Hostetler B, Morre DM, Kelly G. tNOX as a serum marker for detection and estimation of tumor burden in prostate cancer. AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development , Sep 2006 .

Abstract
Jun 2006

Kluger HM, McCarthy M, Alvero A, Divito K, Camp R, Rimm D, Mor G. XIAP is highly expressed in melanoma and is associated with chemotherapy resistance.ASCO Annual Meeting , Jun 2006 .

Abstract
Apr 2006

Mahoney S, Hisheh S, Brown D, Kelly G, Millward M, Dharmarajan A. The effects of phenoxodiol on apoptotic pathways in prostate cancer cells.AACR Annual Meeting , Apr 2006 .

Abstract
Mar 2006

Kelly MG, Mor G, Goss G, Kelly G, Quinn M, O'Malley DM, Baker L, McAlpine JN, Azodi M, Schwartz PE, Rutherford TJ. Phase II evaluation of Phenoxodiol in combination with cisplatin or paclitaxel in women with a history of platinum/taxane refractory/resistant epithelial ovarian,fallopian tube or primary peritoneal cancers. Annual Meeting on Women's Cancer , Mar 2006 ; Abstr. No. 909.

Aug 2005

Goss G, Quinn M, Rutherford T, Kelly M, Kelly G. A randomised phase II study of Phenoxodiol with platinum or taxane chemotherapy in chemoresistant epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. MOGA Annual Scientific Meeting , Aug 2005 .

May 2005

Cabot MC, Yu JY, Kelly GE, Brown DM, Lucas KM, Tanabe K, Allen JD. Phenoxodiol, a synthetic analog of genistein, generates ceramide and is equipotent in wild-type and multidrug-resistant human tumor cells. ASCO Annual Meeting , May 2005 .

Abstract
Apr 2005

Alvero AB, Rutherford T, Mor G. Phenoxodiol-induced apoptosis depends on the simultaneous activation of the mitochondria and degradation of XIAP.AACR Annual Meeting , Apr 2005 .

Abstract
Nov 2004

Davies R, Tulloch A, Frydenberg M, Kelly G. Final results of phase Ib/IIa study of Phenoxodiol in hormone-refractory prostate cancer. AACR Basic, Translational and Clinical Advances in Prostate Cancer Conference , Nov 2004 .

Mar 2004

Rutherford T, O'Malley D, Makkenchery A, Baker L, Azodi M, Schwartz P, Mor G. Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that are resistant to ≥ second line chemotherapy.AACR Annual Meeting , Mar 2004 .

Abstract
Mar 2004

Davies R, Frydenberg M, Tulloch A, Kelly G. Interim results of phase Ib/IIa study of oral Phenoxodiol in patients with late-stage, hormone-refractory prostate cancer. AACR Annual Meeting , Mar 2004 .

Mar 2004

Aguero M, Facchinetti MM, Senderowicz AM. Phenoxodiol, a novel isoflavone, promotes G1/S arrest by upregulation of p21 in head and neck squamous and salivary gland carcinoma cell lines.AACR Annual Meeting , Mar 2004 .

Abstract
Mar 2004

Mor G, Chen W, Sapi E, O'Malley D, Garg M, Rutherford T. Phenoxodiol a chemosensitizer in taxotere-resistant ovarian cancer cells. AACR Annual Meeting , Mar 2004 .

Abstract
Feb 2004

Rutherford T, O'Malley D, Makkenchery A, Baker L, Azodi M, Chambers S, Schwartz P, Mor G. Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that is resistant to second line chemotherapy, SGO Annual Meeting , Feb 2004 .

May 2003

O'Malley DM, Rutherford T, Kamsteeg M, Brown D, Schwartz P, Mor G. Phenoxodiol restores chemo-sensitivity in ovarian cancer. ASCO Annual Meeting , May-Jun 2003 .

Apr 2003

Mor G, Kamsteeg M, Sapi E, Shahabi S, Rutherford T. Phenoxodiol – an isoflavone analogue – induces apoptosis in chemo-resistant ovarian cancer cells. AACR Annual Meeting , Apr 2003 .

Feb 2003

Mor G, Kamsteeg M, Sapi S, Shahabi S, Rutherford T. Phenoxodiol – an isoflavone analogue – induces apoptosis in chemo-resistant ovarian cancer cells. Society of Gynecological Oncologists Meeting , Feb 2003 .

Apr 2002

Hutson TE, Mekhail T, Weiss P, Roman S, Dreicer R, Peereboom D, Olencki T, Kelly G, Ganapathi R, Bukowski R. Phase I study of Phenoxodiol given by constant intravenous infusion in patients with solid neoplasms refactory to standard therapy. AACR Annual Meeting , Apr 2002 .

Oct 2001

Liauw W, Links M, Pirabhahar S, Husband A, Kelly G, de Souza P. Phase I and pharmacokinetic study of weekly Phenoxodiol, a novel isoflav-3-ene, in patients with advanced, solid cancer. ASCO Annual Meeting , Oct 2001 .

Journal Papers

Pracinostat

Jan 2017

Garcia-Manero et al. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes. Cancer. 2017 Jan 17. doi: 10.1002/cncr.30533. [Epub ahead of print]

Abstract
Jul 2016

Sooraj et al. Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat. Mol Cancer Ther. 2016 Jul;15(7):1726-39.

Abstract
Apr 2015

Montalban-Bravo et al. Novel drugs for older patients with acute myeloid leukemia. Leukemia. 2015 Apr;29(4):760-9.

Abstract
Aug 2014

Bose et al. Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leuk Res. 2014 Aug;38(8):862-5.

Abstract
Dec 2013

Odenike. Beyond JAK inhibitor therapy in myelofibrosis. Hematology Am Soc Hematol Educ Program. 2013;2013:545-52.

Full article
Nov 2013

Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.Pediatr Blood Cancer. 2013 Nov;60(11):1868-74.

Abstract
Apr 2013

Okabe et al. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int. 2013 Apr 4;13(1):32.

Full article
Sep 2012

Quintas-Cardama et al. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012 Sep;36(9):1124-7.

Abstract
Jul 2012

Sumanadasa et al. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob Agents Chemother. 2012 Jul;56(7):3849-56.

Full article
May 2012

Novotny-Diermayr et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.Blood Cancer J. 2012 May;2(5):e69.

Full article
Dec 2011

Jayaraman et al. Preclinical metabolism and disposition of SB939 (Pracinostat, an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.Drug Metab Dispos. 2011 Dec;39(12):2219-32.

Full article
Nov 2011

Yong et al. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Ann Oncol. 2011 Nov;22(11):2516-22.

Full article
Jul 2011

Wang et al. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. J Med Chem. 2011 Jul 14;54(13):4694-720.

Abstract
Jul 2011

Novotny-Diermayr et al. Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue.Mol Cancer Ther. 2011 Jul;10(7):1207-17.

Full article
Mar 2011

Razak et al. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer. 2011 Mar 1;104(5):756-62.

Full article
Mar 2010

Novotny-Diermayr et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther. 2010 Mar;9(3):642-52.

Abstract

ME-344

Aug 2016

Manevich et al. Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344. J Pharmacol Exp Ther. 2016 Aug;358(2):199-208.

Abstract
Jul 2016

Jeyaraju et al. A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia. Oncotarget. 2016 Jul 6. [Epub ahead of print]

Full article
Jun 2016

Navarro et al. Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics. Cell Rep. 2016 Jun 21;15(12):2705-18.

Full article
Apr 2015

Bendell et al. Phase 1, open-label, dose escalation, safety, and pharmacokinetic study of ME-344 as a single agent in patients with refractory solid tumors. Cancer. 2015 Apr 1;121(7);1056-63.

Full article
Apr 2015

Lim et al. Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibting mitochondrial NADH: ubiquinone oxidoreductase (Complex I). Am J Cancer Res. 2015;5(2):689-701.

Full article
Aug 2011

Alvero et al. Targeting the mitochondria activates two independent cell death pathways in the ovarian cancer stem cells. Mol Cancer Ther. 2011 Aug;10(8):1385-93.

Full article
Jul 2009

Alvero et al. NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway.Cancer. 2009 Jul;115(14):3204-16.

Full article
Feb 2014

Pant et al. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.Invest New Drugs. 2014 Feb;32(1):87-93.

Full article
Jan 2014

Fotopoulou et al. Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. Ann Ancol. 2014 Jan;25(1):160-5.

Abstract
Aug 2012

Yao et al. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.Mol Oncol. 2012 Aug;6(4):392-404.

Abstract
Mar 2012

Mahoney et al. Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines. J Biosci. 2012 Mar;37(1):73-84.

Abstract
Jan 2012

Russo et al. Flavonoids acting on DNA topoisomerases: recent advances and future perspectives in cancer therapy. Curr Med Chem. 2012 ;19(31):5287-93.

Abstract
Sep 2011

Wang et al. Triphendiol (NV-196), development of a novel therapy for pancreatic cancer.Anticancer Drugs. 2011 Sep;22(8):719-31.

Abstract
May 2011

Kelly et al. Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum/Taxane-Refractory/Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers. Int J Gynecol Cancer. 2011 May;21(4):633-9.

Abstract
Feb 2011

Howes et al. Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer. BMC Clin Pharmacol. 2011 Feb 3;11:1.

Abstract
Sep 2010

de Souza et al. Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. Nutr Rev. 2010 Sep;68(9):542-55.

Abstract
Aug 2010

De Luca et al. Reciprocal relationship between cytosolic NADH and ENOX2 inhibition triggers sphingolipid-induced apoptosis in HeLa cells. J Cell Biochem. 2010 Aug 15;110(6):1504-11.

Abstract
Aug 2010

Aguero et al. Phenoxodiol inhibits growth of metastatic prostate cancer cells. The Prostate. 2010 Aug;70(11):1211-1221.

Abstract
Sep 2009

Georgaki et al. Phenoxodiol, an anticancer isoflavone, induces immunomodulatory effects in vitro and in vivo. J Cell Mol Med. 2009 Sep;13(9B):3929-38.

Abstract
Jul 2009

Herst et al. The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells. Haematologica. 2009 Jul;94(7):928-34.

Full article
May 2009

Morré et al. Phenoxodiol treatment alters the subsequent response of ENOX2 (tNOX) and growth of hela cells to paclitaxel and cisplatin. Mol Biotechnol. 2009 May;42(1):100-9.

Abstract
Apr 2009

Saif et al. Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers.Expert Opin Investig Drugs. 2009 Apr;18(4):469-79.

Abstract
Apr 2009

Silasi et al. Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs.Expert Opin Pharmacother. 2009 Apr;10(6):1059-67.

Abstract
Feb 2009

McPherson et al. Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. Br J Cancer. 2009 Feb 24;100(4):649-55.

Full article
Jan 2009

De Luca et al. Downstream targets of altered sphingolipid metabolism in response to inhibition of ENOX2 by phenoxodiol.Biofactors. 2009;34(3):253-60.

Abstract
Aug 2008

Alvero et al. Anti-tumor activity of phenoxodiol: from bench to clinic. Future Oncol. 2008 Aug;4(4):475-482.

Abstract
Jan 2008

Mor et al. Modulation of apoptosis to reverse chemoresistance. Methods Mol Biol. 2008;414:1-12.

Abstract
Jan 2008

Brown et al. Idronoxil.Drugs Fut. 2008;33(10):844-860.

Abstract
Jan 2008

Alvero et al. Phenoxodiol – a chemosensitizer in the midst of cancer chemoresistance. US Oncology. 2008;4:39-41.

Dec 2007

Herst et al. The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumor cell lines and primary immune cells. Biochem Pharmacol. 2007 Dec 3;74(11):1587-95.

Abstract
Aug 2007

Klein et al. Phenoxodiol protects against Cisplatin induced neurite toxicity in a PC-12 cell model. BMC Neurosci. 2007 Aug 1;8:61.

Full article
May 2007

Yagiz et al. Mouse embryonic fibroblast cells from transgenic mice overexpressing tNOX exhibit an altered growth and drug response phenotype. J Cell Biochem. 2007 May 15;101(2):295-306.

Abstract
Apr 2007

Alvero et al. Phenoxodiol-topotecan co-administration exhibit significant anti-tumor activity without major adverse side effects.Cancer Biol Ther. 2007 Apr;6(4):612-7.

Abstract
Jan 2007

Kluger et al. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med. 2007 Jan 26;5:6.

Full article
Jan 2007

Morré et al. ECTO-NOX target for the anticancer isoflavene phenoxodiol.Oncol Res. 2007;16(7):299-312.

Abstract
Nov 2006

Yagiz et al. Transgenic mouse line overexpressing the cancer-specific tNOX protein has an enhanced growth and acquired drug-response phenotype. J Nutr Biochem. 2006 Nov;17(11):750-9.

Abstract
Nov 2006

Sabbadini. Targeting sphingosine-1-phosphate for cancer therapy. Br J Cancer. 2006 Nov 6;95(9):1131-5.

Full article
Nov 2006

Yu et al. Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells.Anticancer Drugs. 2006 Nov;17(10):1151-61.

Abstract
Oct 2006

de Souza et al. Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancer.Cancer Chemother Pharmacol. 2006 Oct;58(4):427-33.

Abstract
Oct 2006

Shen et al. Phytoestrogen derivatives differentially inhibit arterial neointimal proliferation in a mouse model. Eur J Pharmacol. 2006 Oct 24;548(1-3):123-8.

Abstract
Jun 2006

Mor et al. Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr Opin Investig Drugs. 2006 Jun;7(6):542-8.

Abstract
May 2006

Gamble et al. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumor effects. Int J Cancer. 2006 May 15;118(10):2412-20.

Abstract
May 2006

Choueiri et al. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Ann Oncol. 2006 May;17(5):860-5.

Full article
May 2006

Davies et al. Spotlight on tNOX: a tumor-selective target for cancer therapies.Drug News Perspect. 2006 May;19(4):223-5.

Abstract
Mar 2006

Choueiri et al. Phenoxodiol: isoflavone analog with antineoplastic activity. Curr Oncol Rep. 2006 Mar;8(2):104-107.

Abstract
Feb 2006

Alvero et al. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer. 2006 Feb 1;106(3):599-608.

Full article
Jul 2005

Axanova et al. Growth of LNCaP cells in monoculture and coculture with osteoblasts and response to tNOX inhibitors. Cancer Lett. 2005 Jul 8;225(1):35-40.

Abstract
Jul 2005

Brown et al. Flavonoid compounds in maintenance of prostate health and prevention and treatment of cancer. Mol Biotechnol. 2005 Jul;30(3):253-270.

Abstract
Apr 2005

Aguero et al. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res. 2005 Apr 15;65(8):3364-73.

Full article
Jan 2005

De Luca et al. NAD+/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis.BioFactors. 2005 ;25(1-4):43-60.

Abstract
Sep 2004

Chin-Dusting et al. The isoflavone metabolite dehydroequol produces vasodilatation in human resistance arteries via a nitric oxide-dependent mechanism.Atherosclerosis. 2004 Sep;176(1):45-8.

Abstract
Apr 2004

Wilkinson. Phenoxodiol offers hope for ovarian cancer. Lancet Oncol. 2004 Apr;5(4):201.

Abstract
Jan 2004

Sapi et al. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res. 2004 ;14(11-12):567-78.

Abstract
Jan 2004

Straszewski-Chavez et al. X-linked inhibitor of apoptosis (XIAP) confers human trophoblast cell resistance to Fas-mediated apoptosis. Mol Hum Reprod. 2004 Jan;10(1):33-41.

Full article
May 2003

Constantinou et al. Phenoxodiol, a novel isoflavone derivative, inhibits dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis in female Sprague-Dawley rats. Eur J Cancer. 2003 May;39(7):1012-8.

Abstract
May 2003

Kamsteeg et al. Phenoxodiol – an isoflavone analog – induces apoptosis in chemoresistant ovarian cancer cells. Oncogene. 2003 May 1;22(17):2611-20.

Abstract
Jan 2003

Kelly et al. Flavonoid compounds in prevention and treatment of prostate cancer. Methods Mol Med. 2003;81:377-94.

Full article
Sep 2002

Constantinou et al. Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res. 2002 Sep-Oct;22(5):2581-5.

Abstract